SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending as its highly anticipated earnings report approaches, fueling intense debate and frustration among investors over continuous price declines to new 52-week lows, even as discussions highlight its strong fundamentals and competitive advantages in logistics within the fierce Chinese e-commerce landscape.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending following its CEO Jeff Green's record-breaking $148 million insider share purchase, signaling immense executive confidence, alongside widespread rumors of an OpenAI partnership for ad sales, which is fueling community speculation about a potential short squeeze for the recently oversold stock.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as the community highlights its recent achievement of profitability and the significant growth of its direct revenue business, with Snapchat+ subscriptions now exceeding 25 million and reaching a substantial annualized run rate. Despite these strong financial and user engagement milestones, investors are expressing frustration over the stock's current valuation, fueling discussions of a potential rebound or strategic acquisition given its innovation in AI and AR.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending due to widespread investor confusion regarding its unannounced earnings report and lingering concerns from a recent, though withdrawn, US Pentagon listing. While many express extreme frustration over its performance and geopolitical pressures, a strong counter-narrative highlights the stock as deeply oversold and poised for a rebound fueled by its Qwen AI developments.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending amidst a chaotic earnings release, where initial misreporting of a profit miss was quickly corrected to an in-line EPS and revenue beat, fueling a heated community debate over its significant growth and perceived undervaluation compared to rivals like Robinhood.

CACI International, Inc. is a holding company, which engages in the provision of information solutions and services in support of national security missions and government transformation for intelligence, defense, and federal civilian customers. It operates through the Domestic Operations and International Operations segments. The Domestic Operations segment offers information solutions and services to U.S. federal government agencies, state and local governments, and commercial enterprises to different market areas, including business systems, command and control, communications, cyber security, enterprise information technology, health, intelligence services, investigation and litigation support, logistics and material readiness, and surveillance and reconnaissance. The International Operations segment includes the provision of IT services and proprietary data and software products, serving commercial and government customers. The company was founded by Herb Karr and Harry Markowitz in July 1962 and is headquartered in Reston, VA.

Caci International Inc. - Registered Shares - Class A

CACI is trending due to its recent $2.6 billion acquisition of ARKA Group, a string of significant government contract awards, and recent mixed earnings that typically beat EPS but sometimes missed revenue. The community largely views CACI as a strong long-term play in critical defense and national security technologies like drones and AI, even as investors weigh concerns over government spending cuts and a recent legal verdict.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community eagerly discusses its recently submitted BLA for Deramiocel, fueled by strong HOPE-3 trial data for Duchenne muscular dystrophy and intensifying political pressure on the FDA for accelerated rare disease approvals. Investors are closely watching for an imminent PDUFA date, anticipating a significant re-rating of the stock.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending with a notable price surge, primarily fueled by Ethereum's strong rally and the company's recent significant ETH acquisitions, as the community actively discusses its leveraged exposure to crypto and ongoing concerns about share dilution.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending due to a bullish analyst upgrade emphasizing its leadership in autonomy and future robotaxi services, amplified by Elon Musk's claims about the company's progress in artificial general intelligence. This sparks fervent community debate, with bulls envisioning a new growth era from these innovations, while skeptics highlight declining EV sales and FSD's supervised status, often accusing the stock of being 'manipulated' amidst ambitious projections.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the following segments: Advanced Technology Solutions (ATS), and Connectivity and Cloud Solutions (CCS). The Advanced Technology Solutions (ATS) segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The Connectivity and Cloud Solutions (CCS) segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is trending as positive read-throughs from Broadcom's earnings reinforce its critical role in AI data center infrastructure, boosted by Google's increased CapEx; while the community debates price volatility, analysts point to robust fundamentals and raised guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know

Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Kezar Life Sciences Reports Third Quarter 2025 Financial Results

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for...

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting 2025

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two...

Kezar Life Sciences (KZR) shares rallied 47% on Friday afternoon despite analyst downgrades and price target cuts.Jefferies analyst Maury Raycroft downgraded Kezar Life Sciences to ‘Hold’ from ‘Buy’ with a price target of $7, down from $18. Meanwhile, William Blair analyst Matthew Phipps downgraded Kezar Life Sciences to ‘Market Perform’ from ‘Outperform’ without a price target. Wells Fargo kept its ‘Equal Weight’ rating on the shares but slashed the price target to $5 from $7.Kezar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kezarlifesciences.com/news-releases/news-release-details/kezar-life-sciences-announces-regulatory-update-zetomipzomib">announced</a> on Thursday that it has initiated a process to explore strategic alternatives focused on maximizing shareholder value after being unable to align with the U.S. Food and Drug Administration on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis (AIH). Autoimmune hepatitis is a rare, chronic disease that predominantly affects women and, if left untreated, can lead to cirrhosis, liver failure, and hepatocellular carcinoma.However, the FDA Division of Hepatology and Nutrition cancelled a Type C meeting that was previously scheduled with Kezar in the fourth quarter to discuss a proposed study in AIH, the company said.Earlier this year, Kezar reported positive safety and efficacy data from a clinical trial in patients with refractory or relapsed AIH. However, the regulator requested that Kezar conduct a stand-alone study to define the pharmacokinetics of Zetomipzomib in subjects with significant hepatic impairment before the initiation of another clinical trial in AIH.This study would delay future trials of Zetomipzomib in AIH by approximately two years, the company said, while adding that the requirements put forth by the FDA would also hinder patient enrollment and participation.“While we remain excited about the potential of Zetomipzomib to be the first approved agent in AIH, we lack the resources to extend the development timeline,” CEO Chris Kirk said.The company also said it would be implementing a restructuring plan, including layoffs and other cash conservation measures, as part of the strategic alternative evaluation.William Blair said on Friday that it is surprised to see the FDA refusing to host a Type C meeting. Considering Kezar's current cash balance and liabilities, Blair believes a potential acquisition in the $6 to $7 per share range could be feasible.Wells, however, thinks there could be upside if they return cash to shareholders or in a reverse merger scenario.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KZR">KZR stock</a> soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:589/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_12_46_33_PM_png_393ca210c9.webp" alt="KZR's Sentiment Meter and Message Volume as of 12:46 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="589" height="62"><figcaption>KZR's Sentiment Meter and Message Volume as of 12:46 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that $6.50 to $7 would be a good range for the stock.<stembedurl>https://stocktwits.com/StockBoyAri/message/632736011</stembedurl>Another user expressed doubts over the rally.<stembedurl>https://stocktwits.com/CMCanalyst/message/632743196</stembedurl>KZR stock is down by 9% this year and by about 25% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/artiva-biotherapeutics-gets-price-target-hike-from-wedbush/ch6sW9tR38A">Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive

Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis.

Equity

Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis.


Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

Kezar Life Sciences, Inc. (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today...

All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy

Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 19, 2015 and is headquartered in South San Francisco, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.31	--	--	N/A
Q3 '25	-$2.06	-$1.53	25.64%	BEAT
Q2 '25	-$2.24	-$1.87	16.38%	BEAT
Q1 '25	-$2.61	-$2.27	12.86%	BEAT
Q4 '24	-$2.72	-$2.77	-1.80%	MISSED

KZR
Kezar Life Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest KZR News

KZRKezar Life Sciences Inc